CD34 and myelodysplastic syndrome: We have shown that the AZA-mediated restoration of the pathological signal transducer and activator of transcription (STAT) biosignature in both CD34+ and CD4+ T cells is strongly linked with a favorable clinical outcome in patients with high-risk MDS (40, 41).